ClinicalTrials.gg
CompletedNCT04946396Updated Nov 6, 2026

Effects of Continuous Dexmedetomidine Infusion on Systemic Microvascular Function in Laparoscopic Cholecystecthomy

An interventional study of dexmedetomidine intravenous infusion and 0.9% Sodium Chloride Injection in Laparoscopic Surgery, sponsored by National Institute of Cardiology, Laranjeiras, Brazil. Completed at 1 site in Brazil. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-11-06.

Sponsored by National Institute of Cardiology, Laranjeiras, Brazil · Not applicable, Interventional, and Treatment

How we know

Updated Nov 6, 2026Enrollment updatedEligibility revised+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
66
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Study summary

The microcirculation represents the primary site of exchange of oxygen and nutrients for tissues, and the preservation of microcirculatory perfusion is essential for the maintenance of organ function. The microcirculation is extremely dynamic and may vary according to the individual's temperature, systemic blood pressure, the use of medications, during physical and mental activity, age and pathological processes. In this context, the development of portable microscopes for clinical use has made possible the non-invasive visualization of the microcirculation and tissue perfusion in patients undergoing several highly complex procedures in cardiology, including cardiac surgery with cardiopulmonary bypass, ECMO (Extracorporeal Membrane Oxygenation) and in critically ill patients in intensive care.

CytoCam, for example, is a handheld device that incorporates a darkfield incident light illumination system with a series of high-resolution lenses that project images to a computer dedicated to the system. Dexmedetomidine is a selective agonist of 2-adrenergic receptors in the central nervous system, whose administration results in a reduction in the activity of the sympathetic nervous system and a reduction in the systemic release of catecholamines. Its use in the perioperative period has several beneficial effects, such as reducing neuroendocrine and hemodynamic responses due to anesthesia and surgery, through induction of sedation and analgesia, in addition to reducing the consumption of opioids and anesthetics in general. Several recent studies report that the use of dexmedetomidine in the perioperative period reduces the incidence of postoperative complications, reduces the time on mechanical ventilation and attenuates the neuroendocrine response due to surgical trauma and extracorporeal circulation in patients undergoing cardiac surgery. However, the effects of dexmedetomidine on systemic microcirculation function during its use in anesthesia for elective surgical procedures of medium complexity are not yet known. In conclusion, the hypothesis of the present study is that continuous intravenous infusion of dexmedetomidine during balanced general anesthesia increases the microvascular perfusion flow rate in the sublingual mucosa, representing an increase in systemic microvascular perfusion.

Read the detailed description

CytoCam, is a handheld device that incorporates a darkfield incident light illumination system with a series of high-resolution lenses that project images to a computer dedicated to the system. Dexmedetomidine is a selective agonist of 2-adrenergic receptors in the central nervous system, whose administration results in a reduction in the activity of the sympathetic nervous system and a reduction in the systemic release of catecholamines. Its use in the perioperative period has several beneficial effects, such as reducing neuroendocrine and hemodynamic responses due to anesthesia and surgery, through induction of sedation and analgesia, in addition to reducing the consumption of opioids and anesthetics in general. Several recent studies report that the use of dexmedetomidine in the perioperative period reduces the incidence of postoperative complications, reduces the time on mechanical ventilation and attenuates the neuroendocrine response due to surgical trauma and extracorporeal circulation in patients undergoing cardiac surgery. However, the effects of dexmedetomidine on systemic microcirculation function during its use in anesthesia for elective surgical procedures of medium complexity are not yet known. In conclusion, the hypothesis of the present study is that continuous intravenous infusion of dexmedetomidine during balanced general anesthesia increases the microvascular perfusion flow rate in the sublingual mucosa, representing an increase in systemic microvascular perfusion.

02

Conditions studied

  • Laparoscopic Surgery

Keywords

  • dexmedetomidine
  • microcirculation
  • general anesthesia
  • central alpha-2 agonists
  • tissue perfusion
03

In context

Lead sponsor

National Institute of Cardiology, Laranjeiras, Brazil is the lead sponsor of 21 studies on the registry; 4 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

The criteria were revised on the registry on Nov 6, 2026. See what changed

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adult patients of both sexes (age ≥ 18 and ≤ 75 years)
  • Physical state according to the criteria of the American Association of Anesthesiology
  • Planned surgery of cholecystectomy by videolaparoscopy

Exclusion criteria

Exclusion Criteria:

  • Patient's refusal to participate in the study
  • Inflammation or infection in the sublingual mucosa
  • Emergency surgery
  • Grade III obesity ( ≥39.9 kg/m2)
  • Pregnancy or lactation
  • diseases, malignant neoplasms
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ASA physical status

The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
66 participants (actual)

Study arms

  • Experimental
    dexmedetomidine intravenous infusion

    Patients who will receive continuous intraoperative infusion of dexmedetomidine hydrochloride (0.5 µg/kg/h).

    Drug: dexmedetomidine intravenous infusion

  • Sham comparator
    0.9% saline solution intravenous infusion

    Patients who will receive continuous infusion of 0.9% saline solution (sham group).

    Drug: 0.9% Sodium Chloride Injection

Interventions

  • DrugDexmedetomidineStudies of DexmedetomidineDexmedetomidine pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Dexmedetomidine intravenous infusion during laparoscopic cholecystecthomy

    Also known as: Precedex IV infusion

  • Drug0.9% Sodium Chloride Injection

    0.9%sodium chloride intravenous infusion during laparoscopic cholecystecthomy

    Also known as: 0.9%sodium chloride

06

What researchers measure

Primary outcomes

  1. change in microvascular flow index

    sublingual microvascular density

    Time frame: during surgery

07

Study locations

1 site
  • Eduardo Tibiriçá
    Rio de Janeiro, 22240006, Brazil
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Apr 2022 to primary completion in May 2025, 37 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 22, 2021
First posted
Jun 30, 2021
StartActual
Apr 1, 2022
Primary completionActual
May 30, 2025
CompletionActual
Aug 30, 2025
Last update
Nov 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Enrollment
64→66
Nov 6, 2026
Eligibility
Maximum age 60 Years→75 Years; 1 inclusion criterion edited
What changed in the criteria
Inclusion criteria
  • EditedAdult patients of both sexes (age ≥ 18 and ≤ 6075 years)
Nov 6, 2026
Interventions
Changed 0.9%sodium chloride→0.9% Sodium Chloride Injection
Nov 6, 2026
Show all 1 update
  1. Nov 6, 2026
    Enrollment 64→66
    Eligibility Maximum age 60 Years→75 Years; 1 inclusion criterion edited
    What changed in the criteria
    Inclusion criteria
    • EditedAdult patients of both sexes (age ≥ 18 and ≤ 6075 years)
    Interventions Changed 0.9%sodium chloride→0.9% Sodium Chloride Injection
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT04946396
Lead sponsor
National Institute of Cardiology, Laranjeiras, Brazil
Responsible party
Eduardo Tibirica, MD, PhD (Senior Researcher, National Institute of Cardiology, Laranjeiras, Brazil) — Principal investigator
First posted
Jun 30, 2021
Start date
Apr 1, 2022
Primary completion
May 30, 2025
Completion
Aug 30, 2025
Last update
Nov 6, 2026

Study contacts

EDUARDO TIBIRICA, MD, PhD
principal investigator · National Institute of Cardiology

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Dexmedetomidine

Start the discussion